Vertex Pharmaceutical shares soared 15% Wednesday as Wall Street cheered the results of a late-stage study of its new cystic fibrosis drug, an experimental treatment that targets the underlying cause of the disease rather than …
The odds of shepherding a new drug to market in recent years has fallen to nearly one in 10 — about half of the previous rate, according to a new study released this week. First, a new treatment must survive several layers of …
Pfizer shares were down more than 1% Monday afternoon despite the pharmaceutical giant’s report Sunday of successful late-stage trial results for an experimental rheumatoid arthritis drug. The study showed tasocitinib reduced p…